We have previously shown that activation of the STING pathway in myeloid cells triggered by dsDNA fragments released from BRCA1-deficient ovarian tumor cells upon PARPi is required for the anti-tumor activity of PARPi16. This evidence concerns the gene STING1 and neoplasm.